Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Deferred Taxes (2016 - 2025)

Ani Pharmaceuticals' Deferred Taxes history spans 12 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 113.44% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $14.2 million, up 164.97%, while the annual FY2025 figure was $14.2 million, 164.97% up from the prior year.
  • Deferred Taxes for Q4 2025 was $2.4 million at Ani Pharmaceuticals, down from $18.8 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $18.8 million in Q3 2025 and bottomed at -$17.5 million in Q4 2024.
  • The 5-year median for Deferred Taxes is -$2.8 million (2022), against an average of -$2.6 million.
  • The largest annual shift saw Deferred Taxes crashed 2575.27% in 2022 before it skyrocketed 436.44% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at -$8.1 million in 2021, then skyrocketed by 79.91% to -$1.6 million in 2022, then crashed by 413.6% to -$8.3 million in 2023, then plummeted by 110.04% to -$17.5 million in 2024, then skyrocketed by 113.44% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Deferred Taxes are $2.4 million (Q4 2025), $18.8 million (Q3 2025), and -$3.5 million (Q2 2025).